In this interview, Stephen J. Nicholls and Sotirios Tsimikas discuss AKCEA: Safety and Efficacy of AKCEA-APO(a)-to Lower Lipoprotein(a) Levels in Patients with Established Cardiovascular Disease: A Phase 2 Dose-Ranging Trial.

Subscribe on iTunes | Subscribe on Google Play | Subscribe to ACCEL

Clinical Topics: Diabetes and Cardiometabolic Disease, Dyslipidemia, Advanced Lipid Testing, Lipid Metabolism, Nonstatins

Keywords: ACCELLite, AHA Annual Scientific Sessions, AHA18, Lipoprotein(a), Apolipoproteins A, Cardiovascular Diseases, Cholesterol, LDL, Dyslipidemias

< Back to Listings